Theratechnologies Inc Stock Price, News & Analysis

Theratechnologies (NASDAQ: THTX), a commercial-stage biopharmaceutical company, announced that shareholders have overwhelmingly approved the previously announced plan of arrangement to be acquired by Future Pak affiliate CB Biotechnology, LLC.

The arrangement resolution received strong support with 97.44% approval from shareholders present or represented by proxy, and 97.43% approval from minority shareholders. The transaction's completion remains subject to customary closing conditions, including final approval from the Superior Court of Québec, with a hearing scheduled for September 16, 2025.

Theratechnologies (NASDAQ: THTX) has announced the commercial availability of EGRIFTA WR™, a new formulation of tesamorelin for injection, following FDA approval earlier this year. The drug is specifically indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy.

The improved formulation offers significant advantages over EGRIFTA SV®, including weekly reconstitution instead of daily and less than half the injection volume. EGRIFTA WR™ is supplied as four single-patient-use vials, each containing 11.6 mg of tesamorelin for seven daily 1.28 mg injections, and can be stored at room temperature. The formulation is patent protected until 2033.

The company is facilitating patient transition through its Thera Patient Support® program, offering free training by dedicated Nurse Navigators. EGRIFTA SV® will remain available during a transitional period as managed care plans expand coverage for EGRIFTA WR™.

Theratechnologies (NASDAQ: THTX) announced its upcoming special meeting regarding the acquisition by CB Biotechnology, an affiliate of Future Pak. The deal values THTX at US$3.01 per share in cash, plus contingent value rights (CVR) of up to US$1.19 per share tied to company milestones.

The total consideration represents a 216% premium to THTX's closing price on April 10, 2025. The Board unanimously recommends shareholders vote FOR the arrangement at the September 12, 2025 meeting. The transaction requires approval from 66⅔% of shareholders and a majority of minority shareholders. Support agreements have been secured from directors and officers holding 1.14% of shares, while Soleus Capital (10.4% holder) has indicated intention to support.

Theratechnologies (NASDAQ: THTX) reported Q2 2025 financial results with total revenue of $17.7 million, marking a 19.5% year-over-year decrease. For the first six months of 2025, revenue reached $36.8 million, down 3.9% from 2024. The company achieved positive Adjusted EBITDA for the fifth consecutive quarter, reaching $906,000 in Q2 2025.

EGRIFTA SV® sales declined 31.3% to $11.1 million in Q2, primarily due to supply disruption and higher government chargebacks. Trogarzo® net sales increased 13.4% to $6.6 million. The company reported a net loss of $4.5 million for Q2 2025, compared to a net profit of $987,000 in Q2 2024.

Subsequent to the quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak, leading to the withdrawal of its Fiscal 2025 guidance.

Theratechnologies (NASDAQ: THTX), a commercial-stage biopharmaceutical company, will release its second quarter 2025 financial results on Wednesday, July 9, 2025. The results will cover the period ended May 31, 2025. Due to a recently announced acquisition of the Company on July 2, 2025, management will not host a conference call to discuss the results.

Theratechnologies (NASDAQ: THTX) has entered into a definitive agreement to be acquired by CB Biotechnology, an affiliate of Future Pak, in a deal valued at up to US$254 million. Shareholders will receive US$3.01 in cash per share plus one contingent value right (CVR) worth up to US$1.19 in additional payments tied to specific milestones.

The transaction represents a substantial premium of 126% (cash only) and 216% (including CVR) to THTX's Nasdaq closing price on April 10, 2025. The deal includes milestone payments linked to EGRIFTA franchise performance and combined EGRIFTA-Trogarzo franchise profits over a 36-month period post-closing.

The transaction, expected to close in Q4 2025, requires 66⅔% shareholder approval and court approval. Upon completion, Theratechnologies will become private and delist from both Nasdaq and TSX.

Theratechnologies (NASDAQ: THTX) held its annual virtual shareholders meeting on May 29, 2025. During the meeting, shareholders elected eight directors to the Company's Board for a one-year term. All proposed candidates were successfully elected with approval rates ranging from 77.98% to 84.03%. Joseph Arena received the highest shareholder support with 84.03% votes in favor, while Dawn Svoronos received 77.98% of favorable votes.

Additionally, shareholders appointed KPMG LLP as the Company's auditors for the current fiscal year and approved an omnibus long-term incentive plan benefiting directors, executive officers, and employees of the Company and its subsidiaries.

Theratechnologies (NASDAQ: THTX) presented two significant studies at ACTHIV 2025 focusing on excess visceral abdominal fat (EVAF) in HIV patients. The VAMOS study revealed that 58% of participants had EVAF, which was strongly correlated with reduced muscle quality in aging HIV patients. The analysis showed EVAF had a stronger negative impact on muscle quality compared to subcutaneous fat or BMI. In a separate case series study, the combination of tesamorelin and GLP-1 receptor agonists showed promising results, with patients achieving mean reductions in weight (-13 pounds), BMI (-2.2 kg/m2), and waist circumference (-3.4 inches). Six out of seven patients reached their metabolic and body composition goals, marking the first report of successful dual use of these agents in HIV patients.

Theratechnologies (TSX: TH) (NASDAQ: THTX) has announced its Board of Directors' decision to evaluate a potential company sale through an open and non-exclusive process, following a proposal from Future Pak. The Special Committee, comprising independent and disinterested directors, will oversee the process and provide recommendations to the Board.

The company has expanded its advisory team, adding Raymond James as independent financial advisor and Norton Rose Fulbright as independent legal advisor, alongside existing advisors Barclays and Fasken. Theratechnologies emphasizes that normal operations will continue during these discussions, though there is no guarantee that talks with Future Pak or other parties will result in a transaction.